TJP1 and cancer: LESW can improve the infiltration of cisplatin into deep cancer tissue by interfering with ZO-1 and E-cadherin, causing subsequent changes to their permeability, and increasing the intracellular drug level by reducing the expression of the cisplatin efflux membranous protein MDR-1 (Figure 8).